|
|
 |
|
Viewing report
|
|
|
|
Commercial and Pipeline Perspectives: Lower GI Disorders - Remicade Leads Growth as Novel Biologics Compete for Market Share in Inflammatory Bowel Disease
Datamonitor, July 2004
Introduction
IBD pipeline products are set to challenge Remicade and other existing therapies in the management of the disease. Competition will intensify as CDP870, Antegren, and Humira provide new alternatives in the severe Crohns disease market, and mode of administration will be a key element of product differentiation. In ulcerative colitis, drugs with novel mechanisms will compete for patient share.
Scope
Assessment of epidemiological data and patient potential
Analysis of IBD product pipeline with emphasis on Phase III, including trial results and opinion leader insight
Seven country sales forecasts to 2014
Transcripts of interviews with key IBD opinion leaders in the US, UK, and Japan
Highlights
Antegren has been filed early for multiple sclerosis on the basis of one year data from Phase III studies. Strong uptake of Antegren in multiple sclerosis, followed by approval for Crohns disease in 2006, will put pressure on Biogen Idecs manufacturing capabilities, making swift completion of a new production plant in San Diego crucial.
Patients who received a limited course of induction therapy with Remicade in effect were 'immunized' against the product, and sometimes have not been able to benefit from maintenance therapy when this indication has been approved. This has shrunk the potential patient population for Remicade in Crohns disease, reducing revenues.
A desire to stay with 'tried and trusted' Remicade means that in Crohns disease, switching from Remicade caused by Medicare drug coverage in 2006 will be limited. Uptake of CDP870, Antegren, and Humira in Crohns disease will be boosted by Medicare reform, but probably not at Remicades expense.
Reasons to Purchase
Understand the impact of Medicare reform in the biologics for IBD market and how companies are positioning products for maximum benefit
In a sector heavily dependent on licensing deals, appreciate why big pharma needs to worry about alienating potential partners
Explore IBD clinical trial design and recruitment strategies to understand how to maximize chances for success
Customers who bought this item also bought
Strategic Perspectives: Inflammatory Bowel Disease - The Rise of Remicade
Therapeutic Clinical Intelligence - Inflammatory Bowel Disease
Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief
Stakeholder Opinion: Atopic Dermatitis - A High Level of Unmet Need Creates Market Opportunities
Trial TRAX - Multiple Sclerosis - Clinical Trial Monitoring Brief
Trial TRAX - Rheumatoid Arthritis - Clinical Trial Monitoring Brief
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Pipeline and Commercial Insight: Alzheimers Disease - Scenario Forecasts Reveal Vast Market Potential
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
|
|
|
|
